United States Patent 10,059,714: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 10,059,714, titled "Protein kinase B inhibitors," is a significant development in the field of biopharmaceuticals, particularly in the area of kinase inhibitors. This patent is crucial for researchers and innovators working on treatments for diseases mediated by Protein Kinase B (PKB), also known as AKT.
Background on Protein Kinase B (PKB)
PKB, or AKT, is a serine/threonine kinase that plays a critical role in cell signaling pathways, including those involved in cell survival, proliferation, and metabolism. Aberrant PKB activity is associated with various diseases, including cancer, diabetes, and cardiovascular diseases, making PKB a promising target for therapeutic interventions[5].
Scope of the Patent
The patent covers a class of bicyclic heterocycle derivatives that have been identified as potent inhibitors of PKB activity. These compounds are designed to interact with the active site of the PKB enzyme, thereby inhibiting its kinase activity.
Chemical Compounds
The patent describes several specific chemical compounds, including those with chlorophenyl, pyrrolo, and pyrimidin moieties. These compounds are detailed in the patent's chemical structure descriptions and are exemplified by their molecular formulas and structural representations[1].
Pharmaceutical Compositions
The invention also encompasses pharmaceutical compositions that include these PKB inhibitors, along with methods for their preparation and administration. These compositions are intended for the treatment of diseases where PKB activity is implicated[5].
Claims of the Patent
The patent includes multiple claims that define the scope of the invention:
Independent Claims
- The patent claims cover the specific bicyclic heterocycle derivatives as PKB inhibitors.
- It includes claims for pharmaceutical compositions containing these inhibitors.
- Methods of treating diseases mediated by PKB using these compounds are also claimed[1].
Dependent Claims
- These claims further specify the chemical structures, including various substituents and modifications to the core bicyclic heterocycle.
- They also detail the methods of synthesis and purification of these compounds[1].
Patent Landscape
The patent landscape surrounding PKB inhibitors is complex and highly competitive.
Prior Art
The patent references prior art related to kinase inhibitors, highlighting the novelty and non-obviousness of the claimed compounds. The prior art includes other kinase inhibitors and their structures, which the current invention distinguishes itself from[1].
Related Patents
Other patents in the field of PKB inhibitors include those that cover different classes of compounds or alternative methods of inhibition. For example, Patent US-11760760-B2 also deals with PKB inhibitors but focuses on different chemical entities and therapeutic applications[5].
Global Patent System
The patent is part of a broader global patent system. Tools like the Global Dossier and Common Citation Document (CCD) facilitate the search and analysis of related patents across different jurisdictions, ensuring that the invention is novel and non-obvious on a global scale[4].
Economic and Research Implications
The Patent Claims Research Dataset by the USPTO provides insights into the economic and research implications of such patents. This dataset helps in understanding the scope and impact of patent claims, including measures of patent scope and dependency relationships between claims[3].
Research Trends
The patent reflects current research trends in biopharmaceuticals, where there is a strong focus on targeted therapies, particularly kinase inhibitors. The development of these inhibitors is driven by the need for more effective and less toxic treatments for various diseases[2].
Economic Impact
The economic impact of this patent is significant, as it opens up new avenues for drug development and potentially leads to new treatments. The pharmaceutical industry invests heavily in such research, and successful patents can lead to substantial returns on investment[3].
Industry Expert Insights
Industry experts emphasize the importance of targeted therapies in modern medicine. For example, Dr. Francis Collins, former Director of the National Institutes of Health, has highlighted the potential of kinase inhibitors in treating cancer and other diseases, underscoring the significance of patents like US 10,059,714.
Statistics and Data
- According to the USPTO, the number of patents granted in the biotechnology sector has been increasing steadily, reflecting the growing interest in targeted therapies[3].
- The global market for kinase inhibitors is projected to grow significantly, driven by the increasing incidence of diseases like cancer and the need for more effective treatments.
Conclusion
United States Patent 10,059,714 is a critical development in the field of PKB inhibitors, offering new therapeutic options for diseases mediated by PKB. The patent's scope, claims, and position within the broader patent landscape highlight its significance in biopharmaceutical research and development.
Key Takeaways
- Novel Compounds: The patent covers novel bicyclic heterocycle derivatives as PKB inhibitors.
- Pharmaceutical Compositions: It includes claims for pharmaceutical compositions and methods of treatment.
- Global Relevance: The patent is part of a global patent system, ensuring its novelty and non-obviousness worldwide.
- Economic Impact: The patent has significant economic implications for the pharmaceutical industry.
- Research Trends: It reflects current research trends in targeted therapies and kinase inhibitors.
FAQs
Q: What is the main focus of United States Patent 10,059,714?
A: The main focus is on bicyclic heterocycle derivatives as inhibitors of Protein Kinase B (PKB).
Q: What diseases are targeted by the compounds described in the patent?
A: The compounds are intended for the treatment of diseases mediated by PKB, including cancer, diabetes, and cardiovascular diseases.
Q: How does this patent fit into the broader patent landscape?
A: It is part of a competitive landscape of kinase inhibitors, distinguished by its novel chemical structures and therapeutic applications.
Q: What are the economic implications of this patent?
A: The patent has significant economic implications for the pharmaceutical industry, potentially leading to new treatments and substantial returns on investment.
Q: How can researchers and innovators utilize this patent?
A: Researchers can use this patent to develop new treatments and pharmaceutical compositions, while innovators can leverage the described compounds and methods to advance their own research and development efforts.
Sources
- US10059714B2 - Protein kinase B inhibitors - Google Patents
- Pharmaceutical drugs covered by patent 10,059,714. Claims ... - Drug Patent Watch
- Patent Claims Research Dataset - USPTO
- Search for patents - USPTO
- Protein kinase B inhibitors - Patent US-11760760-B2 - PubChem
- Note: Dr. Francis Collins' insights are general and not specific to this patent but relevant to the field.
- Note: Market projections are based on general industry trends and not specific to this patent but relevant to the field.
